142801-55-6Relevant articles and documents
Analysis of subpocket selectivity and identification of potent selective inhibitors for matriptase and matriptase-2
Duchêne, Dominic,Colombo, Elo?c,Désilets, Antoine,Boudreault, Pierre-Luc,Leduc, Richard,Marsault, Eric,Najmanovich, Rafael
, p. 10198 - 10204 (2014)
We studied the factors affecting the selectivity of peptidomimetic inhibitors of the highly homologous proteases matriptase and matriptase-2 across subpockets using docking simulations. We observed that the farther away a subpocket is located from the catalytic site, the more pronounced its role in selectivity. As a result of our exhaustive virtual screening, we biochemically validated novel potent and selective inhibitors of both enzymes.
Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology
Damalanka, Vishnu C.,Han, Zhenfu,Karmakar, Partha,O'Donoghue, Anthony J.,La Greca, Florencia,Kim, Tommy,Pant, Shishir M.,Helander, Jonathan,Klefstr?m, Juha,Craik, Charles S.,Janetka, James W.
, p. 480 - 490 (2019)
Matriptase and hepsin belong to the family of type II transmembrane serine proteases (TTSPs). Increased activity of these and the plasma protease, hepatocyte growth factor activator (HGFA), is associated with unregulated cell signaling and tumor progression through increased MET and RON kinase signaling pathways. These proteases are highly expressed in multiple solid tumors and hematological malignancies. Herein, we detail the synthesis and structure-activity relationships (SAR) of a dipeptide library bearing Arg α-ketobenozothiazole (kbt) warheads as novel inhibitors of HGFA, matriptase, and hepsin. We elucidated the substrate specificity for HGFA using positional scanning of substrate combinatorial libraries (PS-SCL), which was used to discover selective inhibitors of matriptase and hepsin. Using these selective inhibitors, we have clarified the specific role of hepsin in maintaining epithelial cell membrane integrity, known to be lost in breast cancer progression. These selective compounds are useful as chemical biology tools and for future drug discovery efforts.
INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES
-
Paragraph 0081; 0187, (2016/09/26)
The present invention generally relates to compounds that are useful for inhibiting one or more of hepatocyte growth factor activator, matriptase, hepsin, Factor Xa, or thrombin. The present invention also relates to various methods of using the inhibitor compounds including treating a malignancy, a pre-malignant condition, or cancer by administering an effective amount of the inhibitor to a subject in need thereof.